4′-or nucleosides for the treatment of HCV
US10683321B2 · kind B2 · utility
2Cited by
7References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 17, 2014 |
| Grant date | Jun 16, 2020 |
| Priority date | — |
| Expiry date | Jan 23, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4′-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.